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Abstract
Background: Reported rates of Chlamydia trachomatis are on the rise contradicting the declining
rates of C. trachomatis associated reproductive sequelae in Western countries. Population based
evaluation of the real trend of C. trachomatis infection is important to contemplate prevention
efforts. We studied C. trachomatis occurrence during the past 20 years in Finland comparing
incidence rate data based on serology and reported C. trachomatis laboratory notifications.
Methods: A random sample of 7999 women with two consecutive pregnancies within five years
was selected from the population of the Finnish Maternity Cohort (FMC) serum bank stratified by
calendar year and age. C. trachomatis IgG antibodies were determined by a standard peptide-ELISA.
The reported incidence rates of C. trachomatis infections based on case notifications were obtained
from the National Registry of Infectious Diseases (NIDR).
Results: C. trachomatis seroprevalence rates decreased significantly from 1983 to 2003 both in
women under 23 years of age (23.3% to 9.2%) and in women between 23–28-years of age (22.2%
to 12.6%). However, seroconversion rates increased from 31 per 10000 person years in 1983–85
to 97 per 10000 person years in 2001–2003 (incidence rate ratio 3.2, 95% CI, 1.1–8.7) among the
older age group. Seroconversion rate was highest (264) in 1983–1985 in the younger age-group,
then declined and subsequently increased again (188) in 2001–2003. The incidence based on
seroconversions was in agreement with the reported incidence rates in both age groups.
Conclusion: C. trachomatis seroprevalence rate decreased during 1983–2003 among fertile-aged
women in Finland. During the same time period incidence rates based both on seroconversions and
reported laboratory notifications of diagnosed C. trachomatis infections increased. The discrepancy
between the C. trachomatis incidence and seroprevalence trends warrants further studies.
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Chlamydia trachomatis is a major threat to the reproductive
health of women [1]. National surveillance programs
have largely failed to reduce the disease burden caused by
C. trachomatis [2]. In the Nordic countries, incidence rates
have increased between 1999 and 2005 [3-5]. In Finland,
the incidence of reported C. trachomatis infections
increased by 60% over the last 10 years, peaking in the age
group of 15–24 [6]. Since most chlamydial infections are
asymptomatic [7], true incidence may well be higher than
that based on reports.
In a population based study, we recently reported declin-
ing C. trachomatis antibody prevalence rates [8]. The
decrease was countrywide although small clusters of high
prevalences were seen around large cities and in the
Southeastern part of the country [8]. Similar trend has
been reported from Japan [9]. These reports suggest that
the control efforts may have been efficient.
To clarify the discordance between the reported infection
rates to the National Infectious Disease Register (NIDR)
and the seroprevalence rates, we studied the incidence
rates of C. trachomatis infection by serology using paired
serum bank samples. In order to have a better understand-
ing of the real trend of C. trachomatis infections in the pop-
ulation, we compared incidence rate data based on
serology and reported C. trachomatis laboratory notifica-
tions.
Methods
Finnish Maternity Cohort
More than 98% of pregnant women in Finland (alto-
gether 750000) have participated in the serological
screening for congenital infections (syphilis, HIV, and
hepatitis B) during the first trimester. Approximately 50%
of the women become pregnant again within 5 years of
the first pregnancies and donate 2nd blood samples to the
Finnish Maternity Cohort (FMC) serum bank. The blood
samples have been stored in FMC serum bank at the
National Public Health Institute (KTL) since 1983 and the
FMC serum bank comprises approximately 1.5 million
serum samples.
A total of 275 505 women (< 29 years of age) with paired
serum samples were identified for C. trachomatis antibody
testing as previously described [8]. The FMC cohort was
divided into 28 strata according to calendar year (by 3
year periods i.e. 1983–1985, 1986–1988, 1989–1991,
1992–1994, 1995–1997, 1998–2000, 2001–2003) and
age (< 20, 20–22, 23–25 and 26–28) as described [8]. A
random subsample of 200 or 400 women in each stratum
was obtained. A total of 401 women were excluded
because of missing data. Eventually, 7999 women were
tested for C. trachomatis IgG-antibodies (Table 1).
The study was approved by the institutional ethical com-
mittee and the FMC steering committee.
National Infectious Disease Register
Surveillance of sexually transmitted C. trachomatis infec-
tions is based on mandatory notifications according to a
Communicable Diseases Act and Decree of 1987. Between
1987 and 1997, confirmed C. trachomatis positive cases
were reported to the NIDR by physicians, but from 1997,
by laboratories only (between 1995 and 1997 by both).
The laboratory notification includes personal identifica-
tion number (PIN), gender, age, place of sampling and
test used. Data are updated weekly. Same person may
have been reported more than once if the time interval
exceeded three months. Data after 1995 can be accessed at
http://www3.ktl.fi/stat and is available in fixed subgroups
of age, time period of diagnosis and gender. Data from
earlier years 1987–1994 have been reported elsewhere
[10].
C. trachomatis incidence rates were recorded in two age
groups (≤ 24, and 25–29-year-olds) in four different time
periods (1995–1997, 1998–2000, 2001–2003, 2004–
2006).
Serology
Serum IgG antibodies to C. trachomatis were analyzed in a
single set of experiments by commercial enzyme immu-
noassay (EIA), as previously described [8]. The results
were expressed as mean absorbance (optical density 450
mm) of duplicated samples minus the mean absorbance
Table 1: Number of women (n) with at least 2 pregnancies within 5 years selected randomly by age and calendar time of possible 
seroconversion
Age 1983–85
n
1986–88
n
1989–91
n
1992–94
n
1995–97
n
1998–00
n
2001–03
n
Total
< 20 194 190 198 193 177 184 184 1320
20–22 195 195 193 199 187 194 185 1348
23–25 390 390 388 394 376 365 362 2665
26–28 393 397 384 389 366 367 370 2666
Total 1172 1172 1163 1175 1106 1110 1101 7999Page 2 of 6
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of greater than 1.4 was considered positive [8].
Statistical analysis
Two youngest and two oldest age groups were combined
for statistical analyses into two categories (women below
23 years and those between 23 and 28 years of age; Table
1). Baseline samples (first pregnancy serum sample) were
used to calculate C. trachomatis seroprevalence rates. Dif-
ferences in seroprevalence rates were tested using bino-
mial test for differences in proportions. All 6632 women
who were seronegative at the baseline were eligible for
analysing the incidence rates. C. trachomatis incidence
data was based on seroconversions i.e. the second sample
of the baseline seronegative woman was positive. Inci-
dence rates were estimated by the number of seroconver-
sions divided by person years of follow-up. The time for
each seroconversion was assumed to be in the midpoint
of the two samplings. Crude incidence rate ratio with 95%
confidence interval was calculated. Statistical analyses
were performed using R 2.6.0 (R Development Core
Team, Vienna, Austria) and SPSS 15.0 (SPSS Inc., Chicago,
Illinois, USA).
Results
C. trachomatis seroprevalence trends
C. trachomatis seroprevalences did not differ between
women who were < 23 years of age and those between 23
and 28 years of age (Figure 1A) as their 95% confidence
intervals overlapped at each calendar time point (data not
shown). The highest C. trachomatis seroprevalence rates of
23.3% (CI 19.1–27.5) and 22.2% (19.3–25.1) occurred in
1989–1991 in the younger age group and in 1992–1994
in the older age group. Thereafter, the rates declined sig-
nificantly (p < 0.001) being 9.2% (6.3–12.2) in 2001–
2003 in the younger group and 12.4% (10.0–14.8) in
1998–2000 in the older age group.
C. trachomatis incidence rates based on seroconversions
A total of 161 seroconversions occurred among 6632
(2.4%) women who were seronegative at baseline. The
rate of seroconversions varied from 3.4% to 5.7% in the
younger age group and from 0.8% to 2.3% in the older
age group.C. trachomatis incidence rates were higher in
women who were < 23 years of age than in women
between 23 and 28 years of age through out the whole
time period although the difference decreased towards
2003 (Figure 1B).
C. trachomatis incidence rate based on seroconversions
was 214 (95% CI 172–256) per 10000 person years in the
younger age group and 57 (CI 43–71) per 10000 person
years in the older age group. In the younger age group the
incidence was highest (264 per 10000 person years, CI
142–386) at the beginning of the 1980s (Figure 1B) and
lowest (166 per 10000 person years, CI 68–264) between
1992 and 1994. In 2001–03 the incidence rate increased
to 188 (CI 86–290). However, no statistically significant
time trends were observed.
In the older age group, the incidence was lowest (31, CI
3.8–58) between 1983 and1985. The incidence increased
to 97 (CI 48–146) in 2001–2003 (not significant linear
trend, p = 0.10). The relative difference in the incidence
rates between 1983–1985 and 2000–2003 was significant
(rate ratio 3.2, 95% CI, 1.1–8.7).
C. trachomatis incidence rates based on laboratory 
notifications
The point estimates based on the rates of the NIDR notifi-
cations were in line with C. trachomatis incidence rates
based on seroconversions (Table 2). According to the lab-
oratory notifications, C. trachomatis incidence increased in
both age-groups (< 24 and 25–29 years of age) since
1995–1997 (Table 2). The incidence rates were highest in
women below 24 years of age with 1.5-fold increase from
245 (95% CI 237–253) between 1995 and 1997 to 374
(95% CI 365–383) between 2004 and 2006. A moderate
1.3-fold (CI 1.21–1.43) increase from 57 (CI 53–61) to
70 (CI 66–75) was noted in the women between 25 and
29 of age.
Discussion
We showed that the C. trachomatis incidence rates based
on serology were in line with the incidence rates based on
laboratory notifications. The increasing incidence trends
were at variance with decreasing C. trachomatis seropreva-
lence rates. Our results suggest that the true incidence
rates can best be demonstrated by seroconversions
detected in paired serum samples. The serum bank mate-
rial used is likely to reveal the true population based inci-
dence.
The number of cases with seroconversions followed the
common u-shaped curve of reported C. trachomatis cases
especially among the younger age group [1,4,10]. The
conformity between the FMC and NIDR incidence rates
indicates that the increasing trend is real. Testing of more
individuals and using more sensitive diagnostic tests
would not fully explain the increasing Chlamydia inci-
dence rates.
The discrepancy between reported cases and seropreva-
lence rates is not easy to explain. Such discrepancy have
earlier been reported from British Columbia during an
extensive C. trachomatis control program [1]. Earlier diag-
nosis and treatment may lead to impaired immune
response [1] which then reduces the overall seropreva-
lence rate in the population. Reinfection rates have not
been analysed from the Finnish NIDR. However, increas-Page 3 of 6
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Chlamydia trachomatis a) seroprevalence (%) with the number of prevalent cases and b) incidence (per 10 000 person years) with the number of eroconversions in pregnant women du ing 1983–2003Figure 1
Chlamydia trachomatis a) seroprevalence (%) with the number of prevalent cases and b) incidence (per 10 000 
person years) with the number of seroconversions in pregnant women during 1983–2003.
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dia rates are not explained merely by high reinfection rate.
The observed discrepancy between the incidence rate and
seroprevalence is comparable with the declining trend of
the long-term sequelae of C. trachomatis infection, e.g.
PID, preterm delivery and ectopic pregnancy in Finland
over the last ten years [11,12] and suggest that the infec-
tion burden in the population would be decreasing. How-
ever, it can not be excluded that the increasing incidence
rate reflects changes in the serotype distribution or type
replacement with less pathogenic strains over time. More
research is needed to know whether this could be a conse-
quence of improved diagnosis and efficient treatment of
symptomatic infections caused by virulent C. trachomatis
serotypes linked with stronger symptoms [13-17].
On the other hand, direct comparison of the FMC data
and NIDR data is not straightforward. Most C. trachomatis
infections occur in adolescents [5,18,19] with risk taking
behaviour [20]. Although the FMC serum bank covers
almost all pregnant women and is population based, it
lacks infertile women and to a large part also adolescent
women. Furthermore, contact tracing efforts probably
lead to increasing test numbers and more asymptomatic
cases reported to the NIDR.
Knowledge of C. trachomatis seroprevalence and incidence
trends is extremely important since these trends reflect
prevention efforts in the population. Furthermore, epide-
miologic data are important not only for monitoring C.
trachomatis infection trends but also for identification of
breakthrough mutants [21]. A recent survey among ele-
mentary school students showed that the age of sexual
debut is decreasing and condom use is inconsistent [22].
Increasing rates of reported C. trachomatis infection and
the high incidence based on seroconversions fit into the
picture. There is no national screening program in Finland
although some maternity clinics routinely test women.
Nevertheless, the Ministry of Social Affairs and Health has
prepared a recommendation for opportunistic screening
in Finland but significant reduction in the C. trachomatis
rates is unlikely to take place unless systematic screening
is implemented.
Conclusion
This study confirms the decline of C. trachomatis seroprev-
alence in Finland since the middle of 1990s'. Simultane-
ously demonstrated rising seroconversion rates in
different individuals are in accordance with the reported
laboratory notifications in the NIDR suggesting that the
increasing infection rates are not only due to repeated
infections. Based on our results, population-based C. tra-
chomatis incidence rates can be demonstrated by serocon-
versions detected in paired serum samples. The
discrepancy between the C. trachomatis incidence and
seroprevalence trends warrants further studies.
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Table 2: Chlamydia trachomatis incidence rates per 10 000 person years (95% confidence interval) based on serology or laboratory 
reports
Time period
Age group 1995–1997 1998–2000 2001–2003
FMC < 23-year-olds 166 (68 – 264) 222 (110 – 334) 188 (86 – 290)
23–28-year-olds 33 (4 – 62) 64 (24 – 103) 97 (48 – 146)
NIDR 15–24-year-olds 245 (237–253) 307 (298–315) 374 (365–383)
25–29-year-olds 57 (53 – 61) 64 (60 – 68) 70 (66 – 75)
FMC = Finnish Maternity Cohort; NIDR = National Infectious Disease RegisterPage 5 of 6
(page number not for citation purposes)
BMC Infectious Diseases 2008, 8:169 http://www.biomedcentral.com/1471-2334/8/169Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
References
1. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML: The unex-
pected impact of a Chlamydia trachomatis infection control
program on susceptibility to reinfection.  J Infect Dis 2005,
192(10):1836-1844.
2. World Health Organization: Global prevalence and incidence of
selected curable sexually transmitted infections.  2001 [http:/
/www.who.int/docstore/hiv/GRSTI/003.htm].
3. World Health Organization: 2006 [http://data.euro.who.int/cisid/].
4. Moi H: Care of sexually transmitted infections in the Nordic
countries.  Int J STD AIDS 2001, 12(12):819-823.
5. Fenton KA, Lowndes CM: Recent trends in the epidemiology of
sexually transmitted infections in the European Union.  Sex
Transm Infect 2004, 80(4):255-263.
6. The National Public Health Institute (KTL): Infectious Diseases in
Finland.   [http://www.ktl.fi/attachments/suomi/julkaisut/
julkaisusarja_b/2006/2006b17.pdf].
7. Paavonen J, Eggert-Kruse W: Chlamydia trachomatis: impact on
human reproduction.  Hum Reprod Update 1999, 5(5):433-447.
8. Lyytikainen E, Kaasila M, Koskela P, et al.: Chlamydia trachomatis
seroprevalence atlas of Finland 1983–2003.  Sex Transm Infect
2008, 84(1):19-22.
9. Yamamoto T, Moji K, Kusano Y, Kurokawa K, Kawagoe K, Katamine
S: Trend in Chlamydia trachomatis infection among preg-
nant women in the past ten years in Japan: significance of
Chlamydia trachomatis seroprevalence.  Sex Transm Dis 1998,
25(10):516-521.
10. Hiltunen-Back E, Haikala O, Kautiainen H, Ruutu P, Paavonen J,
Reunala T: Nationwide increase of Chlamydia trachomatis
infection in Finland: highest rise among adolescent women
and men.  Sex Transm Dis 2003, 30(10):737-741.
11. Makinen J: Ectopic pregnancy falls in Finland.  Lancet 1996,
348(9020):129-130.
12. Jakobsson M, Gissler M, Paavonen J, Tapper AM: The incidence of
preterm deliveries decreases in Finland.  Bjog 2008,
115(1):38-43.
13. Millman K, Black CM, Stamm WE, et al.: Population-based genetic
epidemiologic analysis of Chlamydia trachomatis serotypes
and lack of association between ompA polymorphisms and
clinical phenotypes.  Microbes Infect 2006, 8(3):604-611.
14. Geisler WM, Suchland RJ, Whittington WL, Stamm WE: The rela-
tionship of serovar to clinical manifestations of urogenital
Chlamydia trachomatis infection.  Sex Transm Dis 2003,
30(2):160-165.
15. Lan J, Melgers I, Meijer CJ, et al.: Prevalence and serovar distribu-
tion of asymptomatic cervical Chlamydia trachomatis infec-
tions as determined by highly sensitive PCR.  J Clin Microbiol
1995, 33(12):3194-3197.
16. Anttila T, Saikku P, Koskela P, et al.: Serotypes of Chlamydia tra-
chomatis and risk for development of cervical squamous cell
carcinoma.  Jama 2001, 285(1):47-51.
17. Kari L, Whitmire WM, Carlson JH, et al.: Pathogenic diversity
among Chlamydia trachomatis ocular strains in nonhuman
primates is affected by subtle genomic variations.  J Infect Dis
2008, 197:449-456.
18. Hiltunen-Back E, Haikala O, Kautiainen H, Paavonen J, Reunala T: A
nationwide sentinelclinic survey of chlamydia trachomatis
infection in Finland.  Sex Transm Dis 2001, 28(5):252-258.
19. LaMontagne DS, Baster K, Emmett L, et al.: Incidence and reinfec-
tion rates of genital chlamydial infection among women
aged 16–24 years attending general practice, family planning
and genitourinary medicine clinics in England: a prospective
cohort study by the Chlamydia Recall Study Advisory Group.
Sex Transm Infect 2007, 83(4):292-303.
20. Jolly AM, Moffatt ME, Fast MV, Brunham RC: Sexually transmitted
disease thresholds in Manitoba, Canada.  Ann Epidemiol 2005,
15(10):781-788.
21. Soderblom T, Blaxhult A, Fredlund H, Herrmann B: Impact of a
genetic variant of Chlamydia trachomatis on national detec-
tion rates in Sweden.  Euro Surveill 2006, 11(12):E061207 1.
22. National Research and Development Centre for Welfare and Health:
[http://www.stakes.fi/verkkojulkaisut/tyopaperit/T1-2005.pdf].
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/8/169/pre
pubPage 6 of 6
(page number not for citation purposes)
